Lasmiditan Recruiting Phase 3 Trials for Migraine Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04396574A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine